Imatinib (STI571)

Catalog No.S2475 Synonyms: CGP057148B, ST-1571

Imatinib (STI571) Chemical Structure

Molecular Weight(MW): 493.6

Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 35 Publications

6 Customer Reviews

  • Ba/F3-p210T315I cells were treated with indicated concentrations of imatinib with or without PDMP for 24 h. Apoptosis was determined as in A. Data are shown as percentage of sub-G1 for apoptosis in triplicate cultures. *P<0.05.

    FASEB J 2011 25, 3661-3673. Imatinib (STI571) purchased from Selleck.

    Targeting KITLG through c-KIT inhibition using Imatinib; one representative experiment is shown (n = 4).

    Oncotarget, 2016, 7(34):54583-54595. Imatinib (STI571) purchased from Selleck.


    Inhibition of thymidine (a and b) and cytarabine (c and d) uptake with imatinib. K562 cells (a and c) and MEG-01 cells (b and d) were incubated at 37 ◦C for 15 min with imatinib transport buffer, and then incubated with 0.5 Ci of [3H] thymidine or [3H] cytarabine for an additional 5 min in presence of imatinib. Cells were then washed 3 times, lysed and radioactivity associated to cell pellets was quantified. DMSO, dimethylsulfoxide; DPD, dipyridamole.

    Leukemia Res 2012 36, 1311-1314. Imatinib (STI571) purchased from Selleck.

    ZFX regulates imatinib sensitivity and PI3K/Akt signaling pathway in CML cells. Viability of cells transfected with si-ZFX at the indicated doses of imatinib for 24 h (a). Colonies of leukemia cells and imatinib-resistant cells transfected with si-ZFX following treatment with imatinib for 10 days (b). Western blot analysis of Akt, p-Akt, CyclinD1, CyclinE1, Bcl-2, and Caspase-3 in K562 and K562/G01 cells transfected with si-ZFX for 2 days (c). The relative densities of proteins were quantified and normalized to b-Actin (d). Values represented the mean ± SD data from experiments in triplicate. *P\0.05 and **P\0.01

    Cell Biochem Biophys, 2016, 74(2):277-83. Imatinib (STI571) purchased from Selleck.

  • Cell Viability assay results. A2C12, BetaD5, GammaA3, GammaD12, A549, CaCo2, HepG2 cell lines were treated with imatinib mesylate for 24h and 96h.

    Dr. Thomas Kruwel of Fraunhofer. Imatinib (STI571) purchased from Selleck.

    A. Viability curve for the c-Kit mutant MelMS melanoma cell line treated with increasing concentrations of imatinib for 72h (relative to DMSO-treated controls; mean ±sd; n=3) B. MelMS melanoma cells were treated with 50nM imatinib for 24h. The effects on c-Kit, ERK and AKT activation were determined by immunoblotting.

    Dr. Helen Rizos from the university of Sydney. Imatinib (STI571) purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
100 nM 100 nM 600 nM
In vitro

In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. [1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. [2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. [3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EM-2 M1e3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm4TWM2OD1yLkC4PFgh|ryP M3;rfXNCVkeHUh?=
MEG-01 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrMPVNKSzVyPUCuNFg6OjFizszN NXrPW5Z5W0GQR1XS
BV-173 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq0S3FkUUN3ME2wMlE5PzRizszN NF[5OlhUSU6JRWK=
K-562 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMkK0N|Ih|ryP M3ThbXNCVkeHUh?=
NOS-1 M1jGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwNkWzPFMh|ryP M2rF[HNCVkeHUh?=
A498 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnMfI5KSzVyPUKuOVczOjNizszN NGnMfGZUSU6JRWK=
SUP-T1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLudmxKSzVyPUOuPFI6ODdizszN NHPsZplUSU6JRWK=
NCI-H1770 MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTVwNUeyOlIh|ryP NXu1dlBEW0GQR1XS
IMR-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TUN2lEPTB;Nj6yNlE1PyEQvF2= M{D4ZnNCVkeHUh?=
LB2241-RCC NFH6[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vNR2lEPTB;OD6wO|M5PCEQvF2= NV\O[mtHW0GQR1XS
TGBC24TKB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvhNZpKSzVyPUiuN|QxPTJizszN M{jONnNCVkeHUh?=
SCC-15 M4HpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;OSGlEPTB;MUCuO|c5QCEQvF2= M3TSfHNCVkeHUh?=
BB49-HNC NILmNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfITWM2OD1zND6zN|M2KM7:TR?= M33zSXNCVkeHUh?=
ES7 NFLKfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTF2LkezO|kh|ryP NXvCeWtoW0GQR1XS
NCI-H510A M1XTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfCTWM2OD1zNz6yOFQzKM7:TR?= MYjTRW5ITVJ?
TE-441-T M2D6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHZTWM2OD1zNz6yPFg3KM7:TR?= Mle0V2FPT0WU
HH NHzmfJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTEO4FqUUN3ME2xO{4{QTl7IN88US=> M3vhUnNCVkeHUh?=
LC4-1 NIK4RWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3SSpVuUUN3ME2xPE4xPjV{IN88US=> M4DYc3NCVkeHUh?=
NKM-1 NEXkOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF7LkO1OVIh|ryP MmfjV2FPT0WU
RS4-11 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq5UmVKSzVyPUKwMlM{ODhizszN NE\MVJpUSU6JRWK=
ALL-PO MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHlTWM2OD1{MD64NVQ6KM7:TR?= MnK1V2FPT0WU
GDM-1 M3vVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf6T4R2UUN3ME2yNk42QTR3IN88US=> Mnj0V2FPT0WU
DMS-79 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zZVWlEPTB;MkSuOFk{PCEQvF2= M33Pe3NCVkeHUh?=
MPP-89 NXWwPWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ3Lk[4O|Qh|ryP NYHycotzW0GQR1XS
NB10 NHXLe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnRdnJKSzVyPUK2MlQ3QTlizszN NVzGdo93W0GQR1XS
LS-513 M1rqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ4Lki4OFch|ryP NF;YR2xUSU6JRWK=
L-540 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfETZBKSzVyPUK2MlkyPDNizszN NVHOVpZJW0GQR1XS
ES1 M4jyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ5LkWyNUDPxE1? MWnTRW5ITVJ?
NTERA-S-cl-D1 NFXp[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moj5TWM2OD1|MD61NFk{KM7:TR?= M2HBcHNCVkeHUh?=
EW-1 NEf1cVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzmTWM2OD1|Mj65OFU1KM7:TR?= MYjTRW5ITVJ?
Calu-6 NYXaO5JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknXTWM2OD1|Mz6xPFU2KM7:TR?= NWT6SWxlW0GQR1XS
YT NVrGZnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPzTWM2OD1|OD61NlA6KM7:TR?= NYmweoFyW0GQR1XS
TE-6 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTmTWM2OD12MT6yO|k5KM7:TR?= MlG2V2FPT0WU
HT-144 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjBbocxUUN3ME20NU42PDh4IN88US=> MXvTRW5ITVJ?
EW-13 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PwcWlEPTB;NEKuNlc6OSEQvF2= M1qyPXNCVkeHUh?=
KALS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXMbY9GUUN3ME20N{4yOzJ7IN88US=> MoTSV2FPT0WU
MOLT-16 NELKO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nwc2lEPTB;NEWuNFc2OiEQvF2= NVi2SYhuW0GQR1XS
D-336MG NXrUbnQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrxc2lKSzVyPUS1Mlk2QTlizszN NEXrd29USU6JRWK=
TE-11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf1W5ZKSzVyPUS2MlY2OyEQvF2= MoHJV2FPT0WU
EB2 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHXTpVqUUN3ME20Ok43QTlizszN MoXpV2FPT0WU
SK-N-DZ NXHJdYtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfmTWM2OD12OD6wPVYyKM7:TR?= M3;we3NCVkeHUh?=
SW684 NHLYTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXtTWM2OD12OD6yOlk2KM7:TR?= NHPwV2xUSU6JRWK=
EW-18 M36x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXifmFKSzVyPUS4MlQ{QTVizszN MWXTRW5ITVJ?
RL95-2 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHqN5ZvUUN3ME21NE4xPzFizszN MUnTRW5ITVJ?
CHP-126 NUf2dVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTVyLki5NFUh|ryP M2G4NnNCVkeHUh?=
NCI-H1395 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L0XWlEPTB;NUGuO|g{PSEQvF2= NWnPflA6W0GQR1XS
TE-15 NITuTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvQWJpoUUN3ME21Nk4zPTV4IN88US=> Mli3V2FPT0WU
TE-1 MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPnWlB5UUN3ME21N{46PDV3IN88US=> MljCV2FPT0WU
KY821 M{TIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrsRWlKSzVyPU[0MlI2PTJizszN NYfOOnpzW0GQR1XS
LC-2-ad M2KyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XwemlEPTB;NkWuO|YxOSEQvF2= NVfufIVRW0GQR1XS
KP-N-RT-BM-1 M3TOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILjNoJKSzVyPU[2MlY{PjZizszN NV7re|J3W0GQR1XS
SW872 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\ETWM2OD14Nz60N|gzKM7:TR?= NE[ye4VUSU6JRWK=
ES5 M2Kzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\3SGFLUUN3ME22O{43QTZ6IN88US=> NF;0SnpUSU6JRWK=
SK-NEP-1 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTZ6LkO4NFMh|ryP Mme1V2FPT0WU
RPMI-6666 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTdzLkCzNkDPxE1? MV7TRW5ITVJ?
UACC-812 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rGcmlEPTB;N{GuNVYxQSEQvF2= MnTjV2FPT0WU
COLO-829 M3v5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvLTWM2OD15Mj62PVg4KM7:TR?= M4HJ[XNCVkeHUh?=
KP-N-YS NEjBV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\XfndKSzVyPUeyMlcyOzlizszN NXvQRpZDW0GQR1XS
GI-1 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnGTWM2OD15Mz6yPFY5KM7:TR?= MX7TRW5ITVJ?
ETK-1 NFXMTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3voW2lEPTB;N{OuOFk{OiEQvF2= MmD3V2FPT0WU
LXF-289 NVzqOIhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:1XHJGUUN3ME23N{44OjlizszN NXn2RndlW0GQR1XS
CAS-1 NFXuUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\Bb|hKSzVyPUezMlg5PTdizszN NHzhd21USU6JRWK=
EW-22 M1HhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTd2LkexNVUh|ryP NXPVXWdIW0GQR1XS
NCI-H2196 NWfK[HVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7YR5VKSzVyPUe1MlY{PzlizszN M2r1SXNCVkeHUh?=
EoL-1-cell M4K0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLpTWM2OD16MT62PVY{KM7:TR?= NF[4WWtUSU6JRWK=
D-247MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrLOVliUUN3ME24Nk4xOjR6IN88US=> MUfTRW5ITVJ?
Becker MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHmxNm9KSzVyPUiyMlM1QDFizszN M4PDR3NCVkeHUh?=
MDA-MB-134-VI M3LJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr5WoFKSzVyPUiyMlU6QTZizszN MXPTRW5ITVJ?
NCI-H1092 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWxTWM2OD16ND6wNVk4KM7:TR?= M{\Lb3NCVkeHUh?=
KINGS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTh4LkG2NVgh|ryP M1fE[nNCVkeHUh?=
HCC2218 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTh4Lke5NVMh|ryP NHvreWpUSU6JRWK=
GI-ME-N M{jpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP3TWM2OD16Nz63Olk6KM7:TR?= NVfsfGZZW0GQR1XS
AM-38 NVrUPFVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTh6LkO5OVMh|ryP M{P2ZXNCVkeHUh?=
KNS-42 NGPQbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVeyToREUUN3ME24PU4yODF6IN88US=> M{TrOXNCVkeHUh?=
C8166 NHO1UZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTh7Lk[xNlUh|ryP Mm\0V2FPT0WU
Ramos-2G6-4C10 M1njNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr3O|c3UUN3ME24PU45PzF7IN88US=> MkfnV2FPT0WU
CTB-1 NGXuS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTlyLk[zOVch|ryP MVvTRW5ITVJ?
HCE-4 NGr0e4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnacYxKSzVyPUmxMlE{OzZizszN MlvKV2FPT0WU
ECC4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\y[IdKSzVyPUm0MlI2PTVizszN NYnpZ5dHW0GQR1XS
NCCIT MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\6TWM2OD17NT6zNlkzKM7:TR?= MkD5V2FPT0WU
MZ7-mel NES0NGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jxS2lEPTB;OUWuPVA1KM7:TR?= M{L3UXNCVkeHUh?=
COLO-684 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTl4LkKzPFUh|ryP MYrTRW5ITVJ?
SU-DHL-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTl4Lkm4OFIh|ryP MkTFV2FPT0WU
SF126 NGHVflNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDOV3hKSzVyPUm3MlUzOTdizszN NGP2W|lUSU6JRWK=
NMC-G1 NV3UeFI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof2TWM2OD17OD60OVU1KM7:TR?= M2DDO3NCVkeHUh?=
NB14 M32ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXhO3ZSUUN3ME25PE46OjB6IN88US=> NFXOeHNUSU6JRWK=
VA-ES-BJ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXwTWM2OD17OT60NFU3KM7:TR?= Ml7KV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. [5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. [6]


Kinase Assay:


+ Expand

PDGF receptor kinase activity:

PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.
Cell Research:


+ Expand
  • Cell lines: BON-1 cells and NCI-H727 cells
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 − a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).
  • Formulation: Imatinib is diluted in water.
  • Dosages: 70 or 100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (66.85 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 493.6


CAS No. 152459-95-5
Storage powder
in solvent
Synonyms CGP057148B, ST-1571

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00044304 Recruiting Hypereosinophilic Syndrome National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) August 22, 2002 Phase 2
NCT02644525 Not yet recruiting Loaisis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) December 21, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT02538926 Not yet recruiting B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma University of Washington|National Cancer Institute (NCI) January 2017 Phase 2
NCT02924714 Recruiting Gastrointestinal Stromal Tumor Oslo University Hospital January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you please advise whether it is a clear solution for compound dissolved in vehicle 2% DMSO+30% PEG 300+2% Tween 80+ddH2O?

  • Answer:

    For S2475 Imatinib (STI571), it is soluble in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 2mg/ml. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm it in water bath at 45-50C. Then add PEG and Tween. After they mixed well, dilute with water.

  • Question 2:

    What is the difference between S2475 (Imatinib) and S1026 (Imatinib Mesylate)? Are they water soluble?

  • Answer:

    S2475 is free base of Imatinib while S1026 is a solt form of Imatinib. They have exactly the same biological activity but different solubility. S1026 can be dissolved in water, but S2475 is not soluble in water. S2475 can be dissolved in DMSO at up to 3mg/ml.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Imatinib (STI571) | Imatinib (STI571) supplier | purchase Imatinib (STI571) | Imatinib (STI571) cost | Imatinib (STI571) manufacturer | order Imatinib (STI571) | Imatinib (STI571) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID